Trial Profile
Prospective Phase I Study of Gax (Gemcitabine, ABRAXANE, and Xeloda) for Metastatic Pancreatic Cancer Protocol # TSH - APG - 2015-01
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 05 Dec 2016 Planned End Date changed from 1 Nov 2021 to 1 Dec 2016.
- 05 Dec 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2016.
- 05 Dec 2016 Planned initiation date changed from 1 Nov 2015 to 1 Feb 2016.